BNET Industries
Market Cap:$12.3B
Last Fiscal Year Sales:$3.7B
- Public
- US
Dow Jones Description
St. Jude Medical develops medical technology and services that focus on putting more control into the hands of those who treat cardiac, neurological and chronic pain patients worldwide. The company is dedicated to advancing the practice of medicine by reducing risk wherever possible and contributing to successful outcomes for every patient. Headquartered in St. Paul, Minn., St. Jude Medical employs approximately 14,000 people worldwide and has four major focus areas that include: cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation. The St. Jude Medical product portfolio includes implantable cardioverter defibrillators (ICDs), cardiac resynchronization therapy (CRT) devices, pacemakers, electrophysiology catheters, mapping and visualization systems, vascular closure devices, heart valve replacement and repair products, and neurostimulation devices.
Number of Employees 14,000
Peer Companies
NAICS Code Electromedical and Electrotherapeutic Apparatus Manufacturing: 334510
Recent Events
-
Morgan Joseph Initiates Coverage on St. Jude Medical STJ with a Buy; High-Quality Name in...
-
UPDATE: St. Jude Leaves Trade Group AdvaMed In Tax Dispute
-
Zacks Analyst Blog Highlights: Morgan Stanley, Goldman Sachs, St.
-
Was the St. Jude sell-off overdone?
-
Canaccord Adams Downgrades St. Jude Medical Inc. STJ to Hold
-
David Moenning's Daily State of the Markets: Voting With Their Feet
-
Edwards Lifesciences Q3 Profit More Than Doubles; Updates FY09 Outlook
-
Uncertainty in face of reform
-
St. Jude Medical Announces Australian Launch of Devices that Diagnose and Treat Abnormal Heart Rhythms
-
Zacks Analyst Blog Highlights: Fannie Mae, Freddie Mac, St. Jude Medical, Medtronic and Boston...
-
Micell gets investment from St. Jude Medical
-
$15 million infusion for Micell
-
St. Jude Medical to Showcase Complete Cardiovascular Access, Intervention and Hemostasis...
-
FDA clears St. Jude cardiac mapping system
-
St. Jude Medical Announces European Launch of New Version of
-
St. Jude Medical Announces European Launch of New Version of Remote Patient Care Network
-
Notable Analyst Rating Changes 8/26: STJ, GMR, KMT, CP Upgraded; BKC, AMED, MDAS Downgraded
-
UPDATE: St. Jude 2Q Net Up 14%, But ICDs Raise Questions
-
St. Jude Medical Introduces New ICD-Leads Connector
News & Analysis
Filter by
st. jude medical inc. and therapy - All News and Analysis
St. Jude Medical Announces Expanded European CE Mark to Include Therapy Cool Path Bi-Directional Irrigated Ablation Catheter; U.S. Approval for Therapy Cool Path Irrigated Ablation Catheter
- 2007-05-08
ST. PAUL, Minn. -- St. Jude Medical, Inc. (NYSE:STJ) today announced expanded European CE Mark approval to include the Therapy[TM] Cool Path[TM] irrigated ablation catheter with bi-directional steering for use in ablation procedures to treat abnormal heart rhythms.
Clinical Trial Shows Device Optimizes Cardiac Resynchronization Therapy in Less Than Two Minutes; St. Jude Medical Announces QuickOpt Optimization Clinical Trial Results and European Regulatory Approvals at Cardiostim 2006
- 2006-06-16
ST. PAUL, Minn. -- St. Jude Medical, Inc. (NYSE:STJ) today announced the clinical trial results, receipt of European CE Mark approval and European market launch of its QuickOptTM Timing Cycle Optimization. The trial results were presented by James G. Porterfield, M.D., principal investigator in the trial conducted under a U.S....
St. Jude Medical Announces FDA Approval and Market Launch of New Cardiac Ablation Generator and Therapy™ Catheters
- 2005-12-01
ST. PAUL, Minn. -- St. Jude Medical, Inc. (NYSE:STJ) today announced U.S. Food and Drug Administration FDA approval and market release of the IBI-1500T6 Cardiac Ablation Generator and TherapyTM electrophysiology EP catheters, expanding the Company's therapeutic EP portfolio with a new high-power, state-of-the-art ablation system.
St. Jude Medical to Study Benefits of Cardiac Resynchronization Therapy in Heart Failure Patients with Mechanical Dyssynchrony
- 2005-08-23
ST. PAUL, Minn. -- St. Jude Medical, Inc. (NYSE:STJ) today announced first patient enrollment in the Resynchronization Therapy In Normal QRS RETHINQ clinical trial, an important study that may further identify heart failure patients who can benefit from cardiac resynchronization therapy CRT.
St. Jude Medical Showcases Innovative Technologies and Therapies at Society of Thoracic Surgeons Meeting
- 2005-01-20
ST. PAUL, Minn. -- Company Announces Exclusive Marketing Alliance with Raytel Cardiac Services for Mechanical Valve Patient Self-Testing Program
FDA Approves V-V Timing in St. Jude Medical Epic HF and Atlas+ HF Cardiac Resynchronization Therapy Devices
- 2004-11-18
ST. PAUL, Minn. -- St. Jude Medical, Inc. (NYSE:STJ) announced today that it has received U.S. Food and Drug Administration FDA approval to add V-V ventricle to ventricle timing to new models of the St. Jude Medical EpicTM HF and AtlasR+ HF family of cardiac resynchronization therapy devices (CRT-Ds). The...
- 1
Industry Transcripts by Seeking Alpha
-
Medtronic Inc. F2Q10 (Qtr End 10/30/09) Earnings Call Transcript
on Nov 24, 2009about MDT
-
ZOLL Medical Corporation F4Q09 (Qtr End 27/09/09) Earnings Call Transcript
on Nov 11, 2009about ZOLL
-
RadNet, Inc. Q3 2009 Earnings Call Transcript
on Nov 09, 2009about RDNT
-
Cytori Therapeutics Q3 2009 Earnings Call Transcript
on Nov 09, 2009about CYTX
-
StoneMor Partners L.P. 3Q09 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 09, 2009about STON
Glass Door
St. Jude Medical
IndustryTop Rated
- Why So Many Insured People Have Big Medical Debts 5 votes
- Physicians Know We Need Reform 4 votes
- Healthcare Is Still Adding Jobs, Despite Recession 3 votes
- Hospital Chain's Turnaround Raises Health Spending 3 votes
- Healthcare Roundup: Medical Office Space in Demand, Blues Companies See Lower Income, Two Sides of Health Insurance, and More 3 votes
